前列腺癌的特點是進展緩慢，即使是轉移性疾病，五年存活率亦高達 30%。雖然 ADT 能有效控制疾病，但越來越多的證據顯示它亦可能對患者造成許多不良心血管副作用，而由於這些患者存活期延長，這些影響尤其重要。
適應症：Cardiovascular Risk、Prostate Cancer
收案條件
納入條件
- Adult men 18-80 years old
- With histological proven prostate cancer or clinically diagnosed to have prostate cancer,
- Planned for ADT for at least 1 year
排除條件
- Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \<0.85 or previous revascularization or amputation
- Prior neoadjuvant or adjuvant hormone therapy within 1 year before
- Refuse or unable to give written informed consent
- Participation in an investigational program with interventions outside of routine clinical practice
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。